Tseng Chin-Yuan, Wang Kan, Lin Li-Hsiang, Zhang Chuck, White Chelsea C, Wang Ben
H. Milton Stewart School of Industrial & Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
H. Milton Stewart School of Industrial & Systems Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA; Georgia Tech Manufacturing Institute, Georgia Institute of Technology, Atlanta, Georgia, USA.
Cytotherapy. 2024 Oct;26(10):1152-1162. doi: 10.1016/j.jcyt.2024.05.001. Epub 2024 May 6.
Autologous chimeric antigen receptor T-cell therapy presents promising treatment outcomes for various cancers. However, its potential is restrained by unique supply chain challenges, including dynamic patient health conditions and extended turnaround time. These challenges often lead to missed optimal treatment windows, impeding the effective delivery of life-saving treatments. This article presents SimPAC (simulation-based decision support for Patient-centric manufacturing of autologous cell therapies). SimPAC is designed to model and incorporate real-time patient health conditions into the supply chain decisions of autologous chimeric antigen receptor T-cell therapy. SimPAC integrates system dynamics and agent-based simulation techniques, facilitating the adaptation of manufacturing processes and production schedules based on real-time patient health conditions. SimPAC can model various patient disease progressions using parametric functions, nonparametric functions, or tabular data. Additionally, SimPAC offers easy configuration options to model various cell therapy supply chains. We provide two case studies to demonstrate the capabilities of SimPAC and highlight the benefits of patient-centric manufacturing, including improved survival rates and potential economic advantages. However, while the benefits are significant, our study also emphasizes the importance of balancing improved patient outcomes, economic viability and ethical considerations in the context of personalized medicine. SimPAC can be used to explore applications of this approach to diverse therapeutic contexts and supply chain configurations.
自体嵌合抗原受体T细胞疗法为各种癌症带来了有前景的治疗结果。然而，其潜力受到独特的供应链挑战的限制，包括动态的患者健康状况和延长的周转时间。这些挑战常常导致错过最佳治疗窗口，阻碍了挽救生命治疗的有效实施。本文介绍了SimPAC（基于模拟的自体细胞疗法以患者为中心制造的决策支持）。SimPAC旨在对实时患者健康状况进行建模，并将其纳入自体嵌合抗原受体T细胞疗法的供应链决策中。SimPAC整合了系统动力学和基于主体的模拟技术，便于根据实时患者健康状况调整制造工艺和生产计划。SimPAC可以使用参数函数、非参数函数或表格数据对各种患者疾病进展进行建模。此外，SimPAC提供了简单的配置选项，以对各种细胞疗法供应链进行建模。我们提供了两个案例研究，以展示SimPAC的能力，并突出以患者为中心制造的好处，包括提高生存率和潜在的经济优势。然而，尽管好处显著，但我们的研究也强调了在个性化医疗背景下平衡改善患者预后、经济可行性和伦理考量的重要性。SimPAC可用于探索这种方法在不同治疗背景和供应链配置中的应用。
